NasdaqGS:ILMNLife Sciences
German Patent Setback and AI Genomics Ambitions Might Change The Case For Investing In Illumina (ILMN)
In July 2026, Element Biosciences announced that a German court ruled Illumina infringed its DNA sequencing imaging patent, ordering Illumina to halt sales, recall affected MiSeq systems and consumables in Germany, refund customers, and accept joint liability for damages and litigation costs.
At the same time, Illumina highlighted expansion of its Billion Cell Atlas alliance, underscoring how its vast CRISPR-based genomic dataset is becoming core infrastructure for AI-driven drug discovery...